Drugs / INKT
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00631072 | Feb 2008 → Aug 2014 | melanoma | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INKT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00631072 ↗ |
| Modality | Cell therapy | “In vitro expanded autologous invariant natural killer T cells” NCT00631072 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT00631072 ↗ |